CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) has regained compliance with Nasdaq’s minimum bid price requirement, the exchange confirmed.
Under Nasdaq Listing Rule 5550(a)(2), companies must maintain a minimum bid price of $1.00 per share. On March 23, 2026, the Nasdaq Stock Market served CollPlant with a deficiency notice, finding its ordinary shares had traded below the threshold for 30 consecutive business days.
According to Nasdaq staff, CollPlant’s shares recorded closing bid prices at or above $1.00 for ten consecutive business days between September 4 and September 18, satisfying the exchange’s cure period. Nasdaq formally notified the company that the compliance matter is now closed.
Yehiel Tal, chief executive officer, said the restoration of listing status was a priority. "Maintaining our Nasdaq listing is of paramount importance to us, our business collaborators, and our shareholders," he said in a statement published September 22.
The compliance gain comes as the company moves forward with acquisitions and business diversification. CollPlant recently completed its acquisition of LightSolver, a developer of optical laser-based computing architectures, describing the deal as a strategic expansion into high-performance computing and photonics. Its subsidiary CollPlant Ltd. continues to focus on plant-derived recombinant human collagen technologies for 3D bioprinting and medical aesthetics applications.
